At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed May 28, 2026 at 08:00 ET
Cogent Biosciences announced FDA acceptance of its NDA for bezuclastinib in combination with sunitinib for GIST, with Priority Review and a PDUFA date of November 30, 2026. The Phase 3 PEAK trial showed a median PFS of 16.5 months vs 9.2 months (HR=0.50, p<0.0001) and a 46% ORR vs 26% for sunitinib alone. This is a major regulatory milestone for a first-in-class combination that could transform second-line GIST treatment, with no advisory committee planned and no identified review issues.
- FDA accepted NDA for bezuclastinib + sunitinib in GIST with Priority Review; PDUFA date November 30, 2026
- Phase 3 PEAK trial: median PFS 16.5 months (combination) vs 9.2 months (sunitinib alone); HR=0.50 (95% CI: 0.39-0.65, p<0.0001)
- ORR 46% for combination vs 26% for sunitinib monotherapy in imatinib-resistant patients
- No advisory committee planned; FDA communicated no potential review issues identified
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access